Mochida Pharmaceutical Co., Ltd, Tokyo, Japan.
Medilead, Inc, Tokyo, Japan.
Adv Ther. 2022 Nov;39(11):4892-4909. doi: 10.1007/s12325-022-02298-9. Epub 2022 Sep 1.
Although several studies suggest beneficial effects of low-dose estrogen-progestins (LEPs) and progestins on dysmenorrhea in Japanese women, the difference in efficacy between drugs remains unknown.
We identified studies by searching the MEDLINE, Cochrane Library, and ICHUSHI databases and included randomized controlled trials (RCTs) that used total dysmenorrhea score and visual analogue scale (VAS) as outcome measures to evaluate LEPs and progestins for primary and secondary dysmenorrhea. We analyzed results by meta-analysis and network meta-analysis (NMA).
We identified 10 articles on eight RCTs and included seven drugs (six LEPs and one progestin, i.e., dienogest) and placebo in the analysis. Meta-analysis showed improvements in total dysmenorrhea score and VAS for almost all drugs compared with placebo. In NMA, VAS in secondary dysmenorrhea improved more with dienogest than with norethisterone/ethinylestradiol (mean difference - 25.84 [95% CrI - 44.46 to - 7.15]). In the comparison of administration regimens, VAS improved more with progestin-continuous than LEP-cyclic and the surface under the cumulative ranking (SUCRA) of LEP-extended and progestin-continuous appeared to be higher than that of LEP-cyclic.
We confirmed that LEPs and dienogest are effective for primary and secondary dysmenorrhea and suggest that continuous regimens may be more effective than cyclic regimens in improving outcomes.
尽管多项研究表明低剂量雌孕激素(LEP)和孕激素对日本女性痛经有有益影响,但药物疗效的差异尚不清楚。
我们通过检索 MEDLINE、Cochrane 图书馆和 ICHUSHI 数据库,确定了研究,并纳入了使用总痛经评分和视觉模拟评分(VAS)作为结局指标评估 LEP 和孕激素治疗原发性和继发性痛经的随机对照试验(RCT)。我们通过荟萃分析和网络荟萃分析(NMA)进行结果分析。
我们确定了 10 篇关于 8 项 RCT 的文章,包括 7 种药物(6 种 LEP 和 1 种孕激素,即地诺孕素)和安慰剂的分析。荟萃分析显示,与安慰剂相比,几乎所有药物均能改善总痛经评分和 VAS。在 NMA 中,与炔诺酮/炔雌醇相比,地诺孕素治疗继发性痛经时 VAS 改善更明显(平均差异-25.84 [95%置信区间-44.46 至-7.15])。在给药方案比较中,孕激素连续给药比 LEP 周期给药和 LEP 延长期和孕激素连续给药的累积排序曲线下面积(SUCRA)更优,似乎高于 LEP 周期给药。
我们证实 LEP 和地诺孕素对原发性和继发性痛经有效,并提示连续方案可能比周期方案更能改善结局。